Use of OMIC technologies to study arsenic exposure in human populations

Authors

  • Lee E. Moore,

    Corresponding author
    1. Division of Cancer Epidemiology and Genetics (DCEG), US National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    • Correspondence to: L.E. Moore, Division of Cancer Epidemiology and Genetics (DCEG), US National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA. E-mail: moorele@mail.nih.gov

    Search for more papers by this author
  • Sara Karami,

    1. Division of Cancer Epidemiology and Genetics (DCEG), US National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    Search for more papers by this author
  • Craig Steinmaus,

    1. University of California at Berkeley, School of Public Health, 50 University Hall, Berkeley, California
    Search for more papers by this author
  • Kenneth P. Cantor

    1. Formerly with DCEG, US National Cancer Institute, Bethesda, Maryland
    Search for more papers by this author
    • K.P. Cantor is currently at KP Cantor Environmental, LLC, Silver Spring, Maryland.


Abstract

Exposure to arsenic (As) in drinking water is a major health concern. More than 100 million individuals are exposed to levels over the current World Health Organization standard of 10 µg/L worldwide. Arsenic is one of the few agents established as a human carcinogen prior to understanding its mechanism of carcinogenicity. OMIC technologies have enabled researchers to utilize agnostic approaches to explore new, unknown mechanisms through which As causes disease in exposed human populations. In this article, we present recent studies in which OMIC technologies have been used to explore differences in human biological samples to identify markers of exposure, disease susceptibility, and effect in As-exposed and/or diseased tissues. Environ. Mol. Mutagen. 54:589-595, 2013. © 2013 Wiley Periodicals, Inc.

Ancillary